.jpeg)
2026-07-14 05:23:09
Elafibranor is approved for adult patients with primary biliary cholangitis (PBC), used either in combination with ursodeoxycholic acid (UDCA) for those with inadequate response, or as monotherapy for those intolerant to UDCA. The recommended dose is 80 mg once daily orally. No dose adjustment is needed for elderly or renally impaired patients, but use is not recommended in severe hepatic impairment. This summary covers dosing, special population considerations, warnings, and adverse reactions.
2026-06-30 03:05:30
Lusutrombopag is a small molecule oral thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a planned invasive procedure.
2026-06-24 04:44:34
Lusutrombopag is an oral medication indicated for thrombocytopenia in patients with chronic liver disease prior to elective invasive procedures. This guide covers standard dosage, dose adjustment, missed dose management, monitoring protocols and special population considerations.
2026-05-28 02:19:21
Resmetirom (brand name Rezdiffra) is the world's first approved targeted therapy for metabolic dysfunction-associated steatohepatitis (MASH/NASH). This article highlights three critical safety considerations for patients and healthcare professionals to optimize treatment outcomes.
2026-05-25 04:22:45
Discover how Etrasimod (Velsipity) works by sequestering lymphocytes to achieve mucosal healing in moderate-to-severe Ulcerative Colitis. Explore its mechanism, efficacy, and future in Crohn's Disease.
2026-04-30 03:21:05
This article provides a detailed overview of elafibranor's mechanism of action in cholestatic liver diseases such as primary biliary cholangitis (PBC), analyzes its efficacy maintenance characteristics during long-term treatment, clarifies the applicable boundaries of the "drug resistance" concept, and explains key clinical monitoring points.
2025-10-19 11:44:20
